KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial.

Andrew W Bradbury, Jack A Hall, Matthew A Popplewell, Lewis Meecham, Gareth R Bate, Lisa Kelly, Jon J Deeks, Catherine A Moakes, BASIL-3 Investigators

BMJ 388 e080881

PMID39993822
PMCIDPMC11848676
DOI10.1136/bmj-2024-080881
发表日期2025-02-24
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVE: To determine which primary endovascular revascularisation strategy represents the most clinically effective treatment for patients with chronic limb threatening ischaemia who require endovascular femoro-popliteal, with or without infra-popliteal, revascularisation. DESIGN: Three arm, open label, pragmatic, multicentre, randomised, phase 3 superiority trial (BASIL-3). SETTING: 35 UK NHS vascular units. PARTICIPANTS: Patients with chronic limb threatening ischaemia who required endovascular femoro-popliteal, with or without infra-popliteal, revascularisation. INTERVENTIONS: Participants were randomly assigned (1:1:1) to femoro-popliteal plain balloon angioplasty with or without bare metal stenting (PBA±BMS), drug coated balloon angioplasty with or without bare metal stenting (DCBA±BMS), or drug eluting stenting (DES) as their first revascularisation strategy. MAIN OUTCOME MEASURES: The primary outcome was amputation free survival defined as time to first major amputation or death from any cause. Secondary outcomes included the composite components of the primary outcome, major adverse limb events, major adverse cardiac events, and other prespecified clinical and patient reported outcome measures. Serious adverse events were collected up to 30 days after the first revascularisation procedure. RESULTS: Between 29 January 2016 and 31 August 2021, 481 participants were randomised (167 (35%) women, mean age 71.8 years (standard deviation 10.8)). Major amputation or death occurred in 106 of 160 (66%) participants in the PBA±BMS group, 97 of 161 (60%) in the DCBA±BMS group, and 93 of 159 (58%) in the DES group (adjusted hazard ratios: PBA±BMS v DCBA±BMS: 0.84, 97.5% confidence interval 0.61 to 1.16, P=0.22; PBA±BMS v DES: 0.83, 0.60 to 1.15, P=0.20). No differences in serious adverse events were reported between the groups. CONCLUSIONS: Neither DCBA±BMS nor DES conferred significant clinical benefit over PBA±BMS in the femoro-popliteal segment in patients with chronic limb threatening ischaemia undergoing endovascular femoro-popliteal, with or without infra-popliteal, revascularisation. TRIAL REGISTRATION: ISRCTN registry ISRCTN14469736.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig 2

Fig 2 Amputation free survival (AFS) Kaplan-Meier plot and hazard ratio over time fitted assuming non-proportional hazards (intention-to-treat analysis). CI=confidence interval

Top_panel

Amputation free survival (AFS)

Fig 2 · Panel Top_panel

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel Top_panel 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Bottom_panel

Hazard ratio over time

Fig 2 · Panel Bottom_panel

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Bottom_panel 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1 Consolidated standards of reporting trials (CONSORT) diagram. Assessment conducted refers to clinical review, not assessment of primary endpoint
非 KM Figure